Misoprostol Administration Before Hysteroscopy Procedures – A Retrospective Analysis

O uso do misoprostol prévio aos procedimentos histeroscópicos – Um estudo retrospectivo

Quênya Antunes Silveira Inácio¹ Júlia Kefalás Troncon¹ Fernando Passador Valério¹ Helmer Herren¹ Antônio Alberto Nogueira¹ Omero Benedicto Poli Neto¹ Júlio César Rosa e Silva¹

¹Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil

Address for correspondence Júlio César Rosa e Silva, MD, PhD, Av. Bandeirantes, 3900, 14049-900, Ribeirão Preto, SP, Brazil (e-mail: juliocrs@usp.br).

Abstract

Objective To evaluate the use of misoprostol prior to hysteroscopy procedures regarding technical ease, the presence of side effects, and the occurrence of complications.

Methods This is a retrospective, observational, analytical, case-control study, with the review of medical records of 266 patients followed-up at the Gynecological Videoendoscopy Sector of the Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto of the Universidade de São Paulo (HCFMRP – USP, in the Portuguese acronym) from 2014 to 2019, comparing 133 patients who used the drug before the procedure with 133 patients who did not.

Results The occurrence of postmenopausal uterine bleeding was the main indication for hysteroscopy and revealed a statistical difference between groups (p < 0.001), being present in 93.23% of the patients in the study group and in 69.7% of the patients in the control group. Only 2 patients (1.5%) in the study group reported adverse effects. Although no statistical differences were observed regarding the occurrence of complications during the procedure (p = 0.0662), a higher total number of complications was noted in the group that used misoprostol (n = 7; 5.26%) compared with the group that did not use the drug (n = 1; 0.75%), a fact that is clinically relevant. When evaluating the ease of the technique (measured by the complete performance of all steps of the hysteroscopy procedure), it was verified that although there was no difference between groups (p = 0.0586), the control group had more than twice as many incompletely performed procedures (n = 17) when compared with the group that used misoprostol previously (n = 8), which is also clinically relevant.

Conclusion The use of misoprostol prior to hysteroscopy in our service indicated that the drug can facilitate the performance of the procedure, but not without side effects and presenting higher complication rates.

Keywords
► hysteroscopy
► misoprostol
► complications
► side effects

revceived March 19, 2022
accepted after revision March 26, 2022

DOI https://doi.org/10.1055/s-0042-1755462.
ISSN 0100-7203.

© 2022, Federação Brasileira de Ginecologia e Obstetrícia. All rights reserved.
This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited.
(https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda., Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
Introduction

The hysteroscopic procedure emerged ~ 200 years ago, providing the direct visualization of diffuse or focal uterine abnormalities, the anatomical configuration of the cervical canal and the uterine cavity, path permeability, access for biopsies, and direct removal of lesions.\(^1\)–\(^3\) It is considered a minimally invasive procedure, and its use is quite common both in the diagnosis and in the treatment of several conditions, such as abnormal uterine bleeding, the evaluation of infertile patients, surgeries including myomectomy and polypectomy, the diagnosis of endometrial and endocervical hyperplasia and carcinoma, among others, often being performed in clinics or as outpatient follow-up procedures.\(^1\)–\(^3\) This method has an important advantage over other diagnostic techniques: the anatomopathological confirmation of lesions visually identified through guided biopsy.\(^4\)

In order to carry out the procedure, it is often necessary to dilate the cervix, especially in surgical hysteroscopies in which the equipment for performing the procedure is larger than the endocervical canal.\(^5\) The most frequent causes of unsatisfactory exams are cervical stenosis, pain or patient intolerance, bleeding that hinders hysteroscopic view, and technical difficulties.\(^7\) In an attempt to reduce these technical problems and the number of unsatisfactory exams, several methods of cervical dilation have been developed over the years, such as the use of hydrophilic laminators, bladder catheter balloons, and Hegar dilators. These techniques, however, cause great discomfort to patients and increase the risk of complications during the dilation process.\(^1\)–\(^5\),\(^8\) The complication rate varies between 0.3 and 5% according to the definition used, the most common being pain, vagal reaction, uterine perforation, false passage formation, and cervical lacerations. Serious complications, such as organ perforation and pelvic infection, are seldom reported.\(^7\),\(^9\)

Therefore, there was a need to develop new methods of cervical dilation, which should include cervix preparation for a limited time, acceptable for the patient, with ease of administration, quick action, and providing adequate cervical ripening to facilitate the procedure. Misoprostol is one of the most studied agents in this context.\(^1\) It is a synthetic analog of prostaglandin E1 that has been used for cervical preparation prior to performing hysteroscopy because it promotes effective cervical ripening, as well as being an inexpensive, easy to store and administer, and widely available method.\(^4\),\(^5\) The most common adverse effects of misoprostol occur mainly before the procedure and include cramping, abdominal and/or pelvic pain, nausea, changes in intestinal transit, vaginal bleeding of varying intensity, and fever and/or chills. However, these effects are generally described as tolerable and rarely motivate the cancellation or alteration of the procedure.\(^1\),\(^1\)–\(^1\)\(^2\)

According to the scientific literature, misoprostol is effective in cervical ripening in the preoperative period of hysteroscopy, reducing the time needed for cervical dilation and increasing the mean cervical diameter. Nevertheless, the optimal dose, the route of administration, and the ideal time of administration prior to hysteroscopy, in addition to whether...
the drug reduces the rates of pre- and postmenopausal complications, remain unclear, a fact that justifies the importance of carrying out the present study in daily gynecological practice, whose objectives were to assess the ease of the operative hysteroscopic technique with the use of misoprostol, evaluated by the complete performance of the steps of the procedure, to assess the presence of side effects with the use of the drug, and to analyze the occurrence of hysteroscopic complications with its use.5,8

Methods

The present analytical, observational, case-control study was conducted by reviewing the medical records of patients followed up at the Gynecological Videoendoscopy Sector of the HCFMRP-USP in the period from 2014 to 2019. Using a list provided by the Medical Support Service (SAME, in the Portuguese acronym), a total of 508 patients with prescriptions for the drug misoprostol for intrahospital use at the HCFMRP-USP were identified in the analyzed period. By cross-referencing the data of patients followed-up at the Gynecological Videoendoscopy Sector of the same hospital and who had used misoprostol prior to hysteroscopy, 207 patients were identified. The medical records of these 207 patients were reviewed, evaluating: age, parity, type of delivery, time since menopause, associated diseases (systemic arterial hypertension [SAH], type 2 diabetes mellitus [DM2], obesity, and other comorbidities), use of continuous medication, symptoms, postmenopausal bleeding, presence of endometrial thickening, side effects of the drug, procedure complications, and complete performance of the procedure. Among the total patients, 74 lacked data in their medical records or had their hysteroscopy procedures suspended for various reasons unrelated to the use of misoprostol or to the procedure itself and were therefore excluded. The 133 patients included in the study were compared with another 133 age-matched patients also followed-up at the Gynecological Videoendoscopy Section of the HCFMRP-USP who underwent hysteroscopy procedures but who did not use misoprostol previously (control group), regarding the ease of the technique, considered easy when all steps of the hysteroscopy procedure were carried out completely, the presence of side effects, and the occurrence of complications. Patients who used misoprostol before the hysteroscopy did so by vaginally introducing 2 tablets of 200 micrograms (µg) each the night before the procedure, totaling a single dose of 400 µg.

After filling out the study database, which evaluated age, parity, type of delivery, time since menopause, associated diseases (SAH, DM2, obesity, and other comorbidities), the use of continuous medication, symptoms, postmenopausal bleeding, presence of endometrial thickening, drug side effects, procedure complications, and its complete performance, a statistical analysis was carried out using SPSS Statistics for Windows, Version 17.0 (SPSS Inc., Chicago, IL, USA). The distribution of the variables was assessed using the Kolmogorov-Smirnov test. Normally-distributed data were analyzed with the t-test, while abnormally distributed data were evaluated using the Kruskal-Wallis test. Mean values were presented with statistical significance (SS), which was accepted for p < 0.05. Numerical data were presented as mean ± standard deviation (SD) or median and range, depending on their distribution. The chi-squared test was used for variables expressed as percentages, considering a significance level of p < 0.05.

Since this was a retrospective study involving medical record analysis, the Research Ethics Committee of the HCRP-USP was asked to waive the application of informed consent through a Letter of Exemption from the collection of the consent form, given most of the patients were no longer being followed-up at the hospital. The present study, as well as the waiver of written informed consent, were approved by the Research Ethics Committee (REC) of the HCRP-USP on February 17, 2020, under CAAE Protocol No. 28983920.0.0000.5440. All ethical precepts were followed as recommended by the Helsinki Convention.

Results

Regarding the clinical characteristics of the studied patients, no significant difference was observed between those who used misoprostol or not prior to the hysteroscopy procedure in relation to age (p = 0.9005), the number of pregnancies (p = 0.4586), the number of vaginal deliveries (p = 0.5531), the time since menopause (p = 0.9193), history of previous cesarean delivery (p = 0.8723), or regarding the number of prior abortions (p = 0.8528) (Table 1 and 2). When analyzing the comorbidities presented by the patients at the time of hysteroscopy, we observed a significant difference in relation to SAH (p = 0.0041), but not regarding DM2 (p = 0.0622), obesity (p = 0.5082), or other comorbidities (p = 0.3510). The fact that the patients used continuous medications for these comorbidities also did not differ significantly between the 2 groups (p = 0.3023) (Table 2).

Both groups had the same number of patients before and after menopause, with no difference in hormonal status in relation to the use of misoprostol (p = 1.000). The presence of symptoms reported by the patients for the indication of the hysteroscopic procedure showed a difference between the 2 groups (p < 0.001); 93.23% of the patients in the group that used misoprostol had at least 1 symptom versus 72.18% of

Table 1 Clinical characteristics of the studied population

|                      | With misoprostol Mean ± SD | Without misoprostol Mean ± SD | p-value |
|----------------------|----------------------------|-------------------------------|---------|
| Age (years old)      | 60.08 ± 8.5                | 59.95 ± 8.15                 | 0.9005  |
| Pregnancy            | 3.44 ± 1.96                | 3.24 ± 2.47                  | 0.4586  |
| Vaginal delivery     | 2.13 ± 2.17                | 1.96 ± 2.37                  | 0.5531  |
| Time since menopause | 10.98 ± 7.48               | 11.08 ± 8.22                 | 0.9193  |

Abbreviation: SD, standard deviation.
the patients in the control group. Among the most reported symptoms was postmenopausal uterine bleeding, which also showed a significant difference between the 2 groups ($p < 0.001$); 93.23% of the patients in the group that used misoprostol had this symptom versus 69.17% of the patients in the control group. Meanwhile, asymptomatic endometrial thickening showed no statistically significant difference between the 2 groups ($p = 0.6419$). Regarding the adverse

|                        | With misoprostol | Without misoprostol | $p$-value |
|------------------------|------------------|---------------------|-----------|
| Cesarean delivery      |                  |                     |           |
| 0                      | 61               | 69                  | 51.88     |
| 1                      | 33               | 27                  | 20.30     |
| 2                      | 23               | 23                  | 17.29     |
| 3                      | 15               | 13                  | 9.77      |
| 4                      | 1                | 1                   | 0.75      |
| Miscarriage            |                  |                     |           |
| 0                      | 99               | 99                  | 74.44     |
| 1                      | 24               | 23                  | 17.29     |
| 2                      | 8                | 6                   | 4.51      |
| 3                      | 1                | 2                   | 1.50      |
| 4                      | 1                | 2                   | 1.50      |
| 5                      | 0                | 1                   | 0.75      |
| SAH                    |                  |                     |           |
| Yes                    | 111              | 91                  | 68.42     |
| No                     | 22               | 42                  | 31.58     |
| DM2                    |                  |                     |           |
| Yes                    | 63               | 48                  | 36.09     |
| No                     | 70               | 85                  | 63.91     |
| Obesity                |                  |                     |           |
| Yes                    | 44               | 39                  | 29.32     |
| No                     | 89               | 94                  | 70.68     |
| Other comorbidities    |                  |                     |           |
| Yes                    | 89               | 96                  | 72.18     |
| No                     | 44               | 37                  | 27.82     |
| Continuous use of medications |            |                     |           |
| Yes                    | 127              | 123                 | 92.48     |
| No                     | 6                | 10                  | 7.52      |
| Menopause              |                  |                     |           |
| Yes                    | 123              | 123                 | 92.48     |
| No                     | 10               | 10                  | 7.52      |
| Symptoms               |                  |                     |           |
| Yes                    | 124              | 96                  | 72.18     |
| No                     | 9                | 37                  | 27.82     |
| Postmenopausal bleeding|                  |                     |           |
| Yes                    | 124              | 92                  | 69.17     |
| No                     | 9                | 41                  | 30.83     |
| Endometrial thickening |                  |                     |           |
| Yes                    | 124              | 122                 | 91.73     |
| No                     | 9                | 11                  | 8.27      |

Abbreviations: DM2, diabetes mellitus type 2; $n$, number of samples; SAH, systemic arterial hypertension.
effects observed in the patients who used the drug prior to hysteroscopy, only 2 patients (1.5%) reported symptoms: both presented tremors, and 1 presented with symptoms of anxiety. Although no significant difference was observed in relation to the occurrence of complications during the procedure ($p = 0.0662$), a higher total number of complications was observed in the group that used misoprostol ($n = 7; 5.26\%$) compared with the group that did not ($n = 1; 0.75\%$), which is clinically relevant. In the control group, the only reported complication was false passage formation. Meanwhile, in the group that used misoprostol, the most frequent complication was the absence of uterine cavity distension, which was observed in three of the patients. The other observed complications included cervical laceration ($n = 1$), uterine perforation ($n = 2$), and increased fluid absorption ($n = 1$), the latter 2 of which compelled the termination of the procedure. In the group of patients who used misoprostol, false passage formation was not reported ($p = 0.9999$).

Finally, upon evaluating the technical ease (performing all steps of the procedure), we noted that although there was no difference between groups ($p = 0.0586$), the control group had more than twice as many incompletely performed procedures ($n = 17$) when compared with the group that used misoprostol previously ($n = 8$), which is clinically relevant.

**Discussion**

The present study compared 133 women who used misoprostol prior to hysteroscopy with 133 who did not use the medication. This drug is a prostaglandin E1 analog oxytocin that causes changes in the physicochemical structure of cervical collagen. After its administration, misoprostol undergoes de-esterification in the liver into misoprostolic acid. This active metabolite exerts direct action on prostaglandin receptors, leading to the softening and ripening of the cervix, favoring its dilation, in addition to promoting an increase in intracellular calcium, which is responsible for the contraction of uterine muscles. All of these mechanisms enable progressive cervical effacement and dilation.

The systematic review of misoprostol suggests variations in the plasma concentration of this drug depending on the route of administration. Orally, the drug is rapidly and completely absorbed in the gastrointestinal tract; however, it is also quickly and extensively metabolized into its acidic form in the first hepatic pass (de-esterification). A single 400-µg dose of oral misoprostol reaches its peak concentration in 30 minutes and declines in ~120 minutes, remaining at a low level. After vaginal administration, on the other hand, there is a gradual increase in the plasma concentration of misoprostol, reaching a maximum level after 70 to 80 minutes, followed by a slow decline, with the drug level still detectable after 6 hours. It has also been reported that the mean concentration peak via the sublingual route is higher than that achieved via the oral and vaginal routes, which is due to the rapid absorption by the sublingual mucosa, avoiding first-pass metabolism in the liver. When administered rectally, the absorption curve of the drug is similar to that seen when using the vaginal route.

### Table 3 Complications reported after the hysteroscopy procedure

| Complications                      | With misoprostol | Without misoprostol | $p$-value |
|-----------------------------------|------------------|---------------------|-----------|
|                                   | $n$ (133) | % | $n$ (133) | % |           |
| Complications                     |              |          |           |          |           |
| Yes                               | 7           | 5.26     | 1         | 0.75     | 0.0662    |
| No                                | 126         | 94.74    | 132       | 99.25    |           |
| Uterine Cervical Laceration       |              |          |           |          | 0.9999    |
| Yes                               | 1           | 0.75     | 0         | 0        |           |
| No                                | 132         | 99.25    | 133       | 100      |           |
| Absence of uterine cavity distension |            |          |           |          | 0.2619    |
| Yes                               | 3           | 2.26     | 0         | 0        |           |
| No                                | 130         | 97.74    | 133       | 100      |           |
| Uterine perforation               |              |          |           |          | 0.5079    |
| Yes                               | 2           | 1.50     | 0         | 0        |           |
| No                                | 131         | 98.50    | 133       | 100      |           |
| Increased fluid absorption        |              |          |           |          | 0.9999    |
| Yes                               | 1           | 0.75     | 0         | 0        |           |
| No                                | 132         | 99.25    | 133       | 100      |           |
| False passage                     |              |          |           |          | 0.9999    |
| Yes                               | 0           | 0        | 1         | 0.75     |           |
| No                                | 133         | 100      | 132       | 99.25    |           |

Abbreviation: $n$, number of samples.
Corroborating another study carried out with 77 women between January 2005 and March 2006, we did not observe a significant difference in age and the number or type of previous births between the study group and the control group. Although no significant difference was found in the present study regarding pre- and postmenopausal patients, some studies suggest that the use of misoprostol is more effective in dilating the cervix of premenopausal patients, mainly due to the hormonal difference between these women. Regarding the comorbidities presented by the patients at the time of the procedure, only SAH showed significance.

In our study, postmenopausal uterine bleeding was the most prevalent symptom, observed in 93.23% of the patients in the study group and in 69.17% of those in the control group. A case review coordinated by Gimpelson et al. revealed a high incidence of abnormal bleeding, which was observed in 76% of the cases as the chief complaint of patients to undergo hysteroscopy. In addition, a descriptive, cross-sectional study with 26 women showed that the primary complaint of 65.3% of the patients was uterine bleeding.

The occurrence of adverse effects to the use of misoprostol was reported by only 2 patients (1.5%), who presented tremors and anxiety. A meta-analysis evaluating 14 studies showed that significantly more adverse effects were reported when misoprostol was administered compared with procedures without previous use of the drug (odds ratio [OR] = 3.56; 95% confidence interval [CI]: 1.60–7.93). Two other studies described the incidence of adverse effects among women randomized to 200 or 400 µg of misoprostol, but their data were conflicting: the first did not demonstrate a dose-related increase in adverse effects (nausea and abdominal pain) in women randomized to 200 or 400 µg (p = 1.0 and p = 0.055, respectively); however, the second study showed a significant increase in the number of adverse events related only to 400 µg (p = 0.015), such as fever, abdominal pain, diarrhea, nausea, vomiting, and vaginal bleeding. Regarding the administration time, these studies showed that there was no significant difference in the incidence of abdominal cramps (p = 0.64), nausea (p = 0.79), diarrhea (p > 0.99), genital tract bleeding (p = 0.62), and fever (p > 0.99) among women who received misoprostol 12 hours or 3 hours before hysteroscopy. One study with 160 women comparing oral, sublingual, and vaginal administration of the drug concluded that the 3 groups were comparable, and all the adverse effects were similar in all groups and were tolerable. This result is in line with a recent meta-analysis that analyzed 7 randomized, controlled studies involving 568 individuals, evaluating the use of misoprostol in surgical hysteroscopy. Compared with the placebo group, there was an increase in side effects (cramps, vaginal bleeding, nausea, and diarrhea) in the misoprostol group (relative risk [95%CI]: 4.28 [1.43–12.85]).

The incidence of complications in our study was low compared with the mean described in the literature. A total of 7 complications occurred in patients who had previously used misoprostol (5.26%) and in 1 patient who did not use the medication (0.75%). The primary complication reported among patients who used misoprostol was the absence of uterine cavity distension, which occurred in 3 patients. This was also found by Batukan et al. in a randomized, double-blind, placebo-controlled study carried out with the objective of evaluating the efficacy of 400 µg of misoprostol 10 to 12 hours before surgical hysteroscopy in premenopausal women, via the vaginal route. One of the reported disadvantages of vaginal administration was excessive cervical dilation, resulting in difficulty distending the uterine cavity due to fluid leakage through the cervical canal. Another study, prospectively conducted between January 2005 and March 2006 at the Department of Obstetrics and Gynecology of the Faculty of Medicine of Erciyes University, with 77 women, showed that vaginal administration of misoprostol (400 µg) prior to operative hysteroscopy in premenopausal women was superior to the same dose of orally administered misoprostol. The complication rates during cervical dilation, as well as drug side effects, were comparable between the two regimens. Fluid leakage caused by excessive cervical dilation and effacement appeared to be the most important potential disadvantage of vaginal misoprostol. Since the intrauterine pressure did not reach the ideal desired level in these cases, the uterine distension was suboptimal, and therefore, the procedure was more difficult.

In the present study, the other complications observed in patients who used misoprostol were cervical laceration (n = 1; 0.75%), uterine perforation (n = 2; 1.5%), and increased absorption of distension media (n = 1; 0.75%). The patient who did not use misoprostol presented false passage formation as a complication. In a study carried out at Brigham and Women’s Hospital, located in Boston, MA, USA, Propst et al. verified a total number of 925 surgical hysteroscopies between 1995 and 1996, with the occurrence of complications in 2.7% of the patients. Among these complications was cervical laceration, which was present in all cases. In another study carried out by Jansen et al., in which 13,600 hysteroscopies in 82 hospitals in the United States were evaluated in 1997, as well as in the study by Agostini et al., performed in Marseille, France, in which 2,116 surgical hysteroscopies between 1990 and 1999 were analyzed, the most frequent complication among the surgical procedures was uterine perforation, with 0.76% and 1.61% of cases, respectively. The study by Propst et al. also reported complications related to uterine distension media in 1.4% of the surgical hysteroscopy cases. In a randomized, controlled, double-blind study conducted by Oppenberg et al., in which each participant received 1,000 µg of misoprostol or placebo, which was self-inserted vaginally at least 12 hours before operative hysteroscopy, there were a total of 9 (11%) complications reported.

Regarding technical ease, which was evaluated by the complete performance of all steps of the procedure, we observed that although there was no statistically significant difference, the number of patients who did not use misoprostol and did not undergo the complete procedure was more than double in relation to the patients who used the medication (8 patients who used the drug versus 17 patients who did not), which is of substantial clinical relevance. Fernandez et al. reported in a larger series that the administration of 400 µg of oral misoprostol 12 or 24 hours before
surgery or 200 µg of vaginal misoprostol 9 to 10 hours before surgery, respectively, demonstrated greater ease of cervical dilation. However, to date, no placebo-controlled trials have shown a significant decrease in the rate of serious complications such as cervical laceration or perforation.25

The prospective study conducted between January 2005 and March 2006 at the Department of Obstetrics and Gynecology of the Faculty of Medicine of Erciyes University showed that vaginally administered misoprostol (400 µg) prior to operative hysteroscopy in premenopausal women was superior to the same dose of orally administered misoprostol in terms of shorter cervical dilation and surgery duration, as well as the need for cervical dilation for No. 9 Hegar.15 Other previous studies comparing patients who used misoprostol or placebo previously to prepare the cervix, as evidenced by Uckuyu et al,26 in Ankara, Turkey, also show a relevant rate of failure in dilation with Hegar dilators, especially in patients who had had previous cesarean sections. In the aforementioned study, the reported failure rate of cervical dilation using Hegar dilators was 25%.26

Our study had some limitations, such as the absence of a patient-reported pain assessment, given most of the analyzed patients underwent the procedure in the operating room under anesthesia; lack of evaluation of different doses and routes of administration of misoprostol, since all of the patients used the drug at a dose of 400 µg via the vaginal route; the absence of evaluation of the time of misoprostol administration, seeing that, in all patients, the drug was introduced the night before the procedure. Costa et al.27 conducted a randomized study with 120 postmenopausal women who received 200 µg of vaginal misoprostol or placebo 8 hours before outpatient hysteroscopy. There was a significant reduction in the pain scale during the procedure, a fact that would facilitate the performance of outpatient surgical procedures. In 2018, Fouda et al.28 evaluated the effect of timing of vaginal misoprostol administration (3 hours versus 12 hours) before diagnostic hysteroscopy in nulliparous women, who are at increased risk for cervical canal stenosis. The group of women given the drug just 3 hours before hysteroscopy reported more pain during the procedure than those given the medication 12 hours earlier. However, the pain intensity 30 minutes after the procedure, its mean duration, and the occurrence of side effects to misoprostol were similar between the 2 groups. The passing of the hystroscope through the cervical canal was also assessed by the examiners and was found to be easier in the 12-hour group.

**Conclusion**

The use of misoprostol prior to hysteroscopy in our service showed that the drug can facilitate the performance of the procedure; however, this drug is not free from side-effects and higher complication rates. Also, misoprostol is a well-tolerated drug. We agree with most authors that there is a need for further studies to better identify the ideal dose, route of administration, and time to indicate misoprostol before the procedure.

**Contributions**

All authors contributed to the design of the study, were involved in the data collection, data analysis and/or interpretation. Also, all authors contributed to the writing/substantive editing and review of the manuscript and approved the final draft of the manuscript.

**Conflict of Interests**

The authors have no conflict of interests to declare.

**Acknowledgments**

The present study was carried out with the support of de Coordination for the Improvement of Higher Education Personnel - Brazil (CAPES, in the Portuguese acronym).

**References**

1. Martins FN, Martins NN. Histeroscopia diagnóstica [Internet]. CoimbraFederação das Sociedades Portuguesas de Obstetrícia e Ginecologia2010 [cited 2021 Dec 12]. p. 359–71. Available from: http://www.fspog.com/fotos/editor2/cap_42.pdf
2. Gane R, Kerner H, Kelson G, Feit H, Keidar R, Bar J, et al. Different routes of misoprostol for same-day cervical priming prior to operative hysteroscopy: a randomized blind trial. J Minim Invasive Gynecol. 2017;24(03):455–460. Doi: 10.1016/j.jmig.2016.12.024
3. Valente EP. Uso de misoprostol vaginal para redução da dor em histeroscopia diagnóstica na menopause: ensaio clínico randomizado, triplamente mascarado, controlado com placebo [dissertação]. Recife: Instituto Materno Infantil Professor Fernando Figueiredo; 2017
4. Bastu E, Celik C, Nehir D, Dogan M, Yuksel B, Ergun B. Cervical priming before diagnostic operative hysteroscopy in infertile women: a randomized, double-blind, controlled comparison of 2 vaginal misoprostol doses. Int Surg. 2013;98(02):140–144. Doi: 10.9738/INTSURG-D-12-00024.1
5. Zhuo Z, Yu H, Jiang X. A systematic review and meta-analysis of randomized controlled trials on the effectiveness of cervical ripening with misoprostol administration before hysteroscopy. Int J Gynaecol Obstet. 2016;132(03):272–277. Doi: 10.1016/j.ijgo.2015.07.039
6. Fradique A. Histeroscopia cirúrgica [Internet]. CoimbraFederação das Sociedades Portuguesas de Obstetrícia e Ginecologia2010 [cited 2021 Dec 12]. p. 511–33. Available from: http://www.fspog.com/fotos/editor2/cap_49.pdf
7. Clark TJ, Voit D, Gupta JK, Hyde C, Song F, Khan KS. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. JAMA. 2002;288(13): 1610–1621. Doi: 10.1001/jama.288.13.1610
8. Allen R, O'Brien BM. Uses of misoprostol in obstetrics and gynecology. Rev Obstet Gynecol. 2009;2(03):159–168
9. Costa AA. Estudo randomizado, duplamente mascarado, placebo controlado do uso do misoprostol versus placebo para histeroscopia diagnóstica em mulheres na pós-menopausa [tese]. Campinas: Universidade Estadual de Campinas; 2006
10. Moreira AR. O uso de misoprostol em histeroscopia: revisão do seu papel em contexto diagnóstico e cirúrgico [monografia]. Porto: Universidade do Porto; 2018
11. de Albuquerque LG, Hardy E, Bahamondes L. Histerossonografia: avaliação da cavidade uterina com sangramento anormal. Rev Assoc Med Bras (1992). 2006;52(04):247–250. Doi: 10.1590/S0104-423020060004000025
12. Angioni S, Loddo A, Milano F, Piras B, Minerba L, Melis GB. Detection of benign intracavitary lesions in postmenopausal women with abnormal uterine bleeding: a prospective comparative study on outpatient hysteroscopy and blind biopsy.

Rev Bras Ginecol Obstet Vol. 44 No. 12/2022 © 2022. Federação Brasileira de Ginecologia e Obstetrícia. All rights reserved.
Koch DM, Rattmann YD. Uso do misoprostol no tratamento da hemorragia pós-parto: uma abordagem farmacoepidemiológica. Einstein (São Paulo). 2020;18:eAO5029. Doi: 10.31744/einstein-journal/2020AO5029
Souza AS, Amorim MM, Costa AA, Noronha Neto C. Farmacocinética e farmacodinâmica do misoprostol em obstetricia. Femina. 2019;37(12):679–684
Batukan C, Ozgun MT, Ozcelik B, Aygen Y, Turkylmaz C. Cervical ripening before operative hysteroscopy in premenopausal women: a randomized, double-blind, placebo-controlled comparison of vaginal and oral misoprostol. Fertil Steril. 2008;89(04):966–973. Doi: 10.1016/j.fertnstert.2007.03.099
Gimpelson RJ, Rappold HO. A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. A review of 276 cases. Am J Obstet Gynecol. 1988;158(3 Pt 1):489–492. Doi: 10.1016/0002-9378(88)90011-7
Bezerra Júnior AL, Costa AA, Fernandes GC, Santos JV, Pereira TM. Resultados intra e pós-operatórios e a frequência de complicações em pacientes pré e pós-menopausadas submetidas à histeroscopia cirúrgica no IMIP [tcc]. Recife: Instituto Materno Infantil de Pernambuco; 2019
De Silva PM, Wilson L, Carnegy A, Smith PP, Clark TJ. Cervical dilatation and preparation prior to outpatient hysteroscopy: a systematic review and meta-analysis. BJOG. 2021;128(07):1112–1123. Doi: 10.1111/1471-0528.16604
Selk A, Kroft J. Misoprostol in operative hysteroscopy: a systematic review and meta-analysis. Obstet Gynecol. 2011;118(04):941–949. Doi: 10.1097/AOG.0b013e31822f3c7b
Song T, Kim MK, Kim ML, Jung YW, Yoon BS, Seong SJ. Effectiveness of different routes of misoprostol administration before operative hysteroscopy: a randomized, controlled trial. Fertil Steril. 2014;102(02):519–524. Doi: 10.1016/j.fertnstert.2014.04.040
Propst AM, Liberman RF, Harlow BL, Ginsburg ES. Complications of hysteroscopic surgery: predicting patients at risk. Obstet Gynecol. 2000;96(04):517–520. Doi: 10.1016/s0029-7844(00)00958-3
Jansen FW, Vredevoogd CB, van Ulzen K, Hermans J, Trimbos JB, Trimbos-Kemper TC. Complications of hysteroscopy: a prospective, multicenter study. Obstet Gynecol. 2000;96(02):266–270. Doi: 10.1016/s0029-7844(00)00865-6
Agostini A, Bretele F, Cravello L, Ronda I, Roger V, Blanc B. [Complications of operative hysteroscopy]. Presse Med. 2003;32(18):826–829
Oppengard KS, Nesheim BL, Istré O, Vrigstad E. Comparison of self-administered vaginal misoprostol versus placebo for cervical ripening prior to operative hysteroscopy using a sequential trial design. BJOG. 2008;115(05):663.e1–9. Doi: 10.1111/j.1471-0528.2007.01628.x
Fernandez H, Alby JD, Tournoux C, Chauveaud-Lambling A, DeTayrac R, Frydman R, et al. Vaginal misoprostol for cervical ripening before operative hysteroscopy in pre-menopausal women: a double-blind, placebo-controlled trial with three dose regimens. Hum Reprod. 2004;19(07):1618–1621. Doi: 10.1093/humrep/deh302
Uckuyu A, Ozcimen EE, Sevinc FC, Zeyneloglu HB. Efficacy of vaginal misoprostol before hysteroscopy for cervical priming in patients who have undergone cesarean section and no vaginal deliveries. J Minim Invasive Gynecol. 2008;15(04):472–475. Doi: 10.1016/j.jmig.2008.03.001
Costa HdeL, Costa LO. [Hysteroscopy in menopause: analysis of the techniques and accuracy of the method]. Rev Bras Ginecol Obstet. 2008;30(10):524–530. Doi: 10.1590/s0100-72032008001000008
Fouda UM, Elsetohy KA, Elshaer HS, Hammad BEM, Shaban M, Youssef MA, et al. Misoprostol prior to diagnostic office hysteroscopy in the subgroup of patients with no risk factors for cervical stenosis: a randomized double-blind placebo-controlled trial. Gynecol Obstet Invest. 2018;83(05):455–460. Doi: 10.1159/000480234